New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
06:23 EDTBAYRYBayer extends offer for Algeta takeover offer
The Bayer Group is extending the offer period for the voluntary takeover offer for Norwegian pharmaceutical company Algeta ASA, Oslo, by two days to February 26 at 09:00 CET. Except for the extension of the offer period, all other terms and conditions of the offer remain unchanged. Bayer is offering NOK 362 in cash per share for all issued Algeta shares. As of February 24 at 7:40 CET, Bayer had received acceptances and pre-acceptances of the offer for approximately 40,485,490 shares, representing approximately 92.17 % of Algeta's share capital in response to its voluntary takeover offer. The acceptance level is based on preliminary numbers and may be subject to adjustments. Currently, Bayer does not own any shares in Algeta ASA. All regulatory approvals required for completion of the proposed acquisition have been obtained. However, the offer is still subject to certain closing conditions, which are set out in the offer document published on January 20. These stipulate, among other things, that at least 90 % of Algeta's share capital must be tendered to Bayer. It remains to be verified by means of the final acceptance numbers that this condition is satisfied. Bayer maintains its right to further extend the offer period as set out in the offer document. Subject to the fulfillment or waiver of all offer conditions, Bayer expects to complete the acquisition in the first quarter of 2014.
News For BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
11:36 EDTBAYRYBayer sees FY15 sales EUR 46
The company expects positive currency effects on sales of about 3% compared with the previous year. Bayer plans to raise EBITDA before special items by a low- to mid-teens percentage, allowing for expected positive currency effects of about 2 percent. Bayer aims to increase core earnings per share by a low-teens percentage, allowing for expected positive currency effects of around 3%.
11:35 EDTBAYRYBayer reports FY14 net income EUR 3.43B vs. EUR 3.19B last year
Subscribe for More Information
06:30 EDTBAYRYBayer says flotation of MaterialScience 'proceeding on schedule'
Subscribe for More Information
February 20, 2015
07:23 EDTBAYRYAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
06:29 EDTBAYRYBayer close to selling diabetes unit to Panasonic, Bloomberg says
Subscribe for More Information
February 19, 2015
18:25 EDTBAYRYPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
16:50 EDTBAYRYSanofi appoints Olivier Brandicourt CEO
Subscribe for More Information
14:53 EDTBAYRYBayer near sale of diabetes unit to KKR backed venture, Bloomberg says
Subscribe for More Information
14:01 EDTBAYRYBayer near sale of diabetes unit to KKR's Panasonic Healthcare, Bloomberg says
Subscribe for More Information
February 13, 2015
08:23 EDTBAYRYPiper Jaffray biotech/healthcare analysts hold analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use